Abstract:Gene directed enzyme pro-drug therapy (GDEPT) is one of the adjuvant therapeutic regimens for advanced prostate adenocarcinoma, and this research intended to explore how to apply targeting therapy of prostate adenocarcinoma under the mediation of a promoter/enhancer of prostate-specific membrane antigen (PSMA(EP)) as a specific regulatory element. Recombinant adenoviruses (Ad-PSMA(E-P)-enhanced green fluorescent protein [EGFP], Ad-CMV-EGFP, Ad-PSMA(E-P)-CD, and Ad-CMV-CD) were constructed and could express cytosine deaminase (CD) or the EGFP reporter gene driven by a PSMAEP or cytomegalovirus (CMV) promoter. LNCaP, CL-1, MCF-7, and A549 were infected with CD-produced recombinant adenoviruses and treated with pro-drug 5-fluorocytos,ine (5-FC) in vivo and vitro; then, the growth inhibition of the cells and the cell cycle variation were assessed by an [3-(4,5dimethylthazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) assay and flow cytometry. Growth suppression of the xenograft tumor was also adopted to evaluate the efficiency of the suicide system. Morphologic changes after treatment in vivo were assessed with hematoxylin and eosin staining. In the 4 examined cancer cell lines, PSMA-positive prostate cancer cells LNCap and CL-1 were exclusively sensitive to the Ad-PSMA(E-P)-CD/5-FC system. The S phase of cell cycle arrest was thought to be involved in the cytotoxicity of 5-fluorouracil (5-FU) converted from 5-FC by CD. CL-1 implanted Athymic BALB/c mice showed growth inhibition of tumors when they were treated with the Ad-PSMA(E-P)-CD/5-FC system without systemic conversion toxicity. The PSMA-based, CD-produced adenovirus, deserving further investigation in the future, might be a good candidate and flow cytometry. Growth suppression of the xenograft tumor was also adopted to evaluate the efficiency of the suicide system. Morphologic changes after treatment in vivo were assessed with hematoxylin and eosin staining. In the 4 examined cancer cell lines, PSMA-positive prostate cancer cells LNCap and CL-1 were exclusively sensitive to the Ad-PSMA(E-P)-CD/5-FC system. The S phase of cell cycle arrest was thought to be involved in the cytotoxicity of 5-fluorouracil (5-FU) converted from 5-FC by CD. CL-1 implanted Athymic BALB/c mice showed growth inhibition of tumors when they were treated with the Ad-PSMA(E-P)-CD/5-FC system without systemic conversion toxicity. The PSMA-based, CD-produced adenovirus, deserving further investigation in the future, might be a good candidate for targeting gene therapy of prostate adenocarcinoma.

[Preparation and characterization of Ad-ERα-36-Fc-GFP].

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

The Construction and Characterization of a Novel Adenovirus Vector of Artificial Microrna Targeting EGFR.

AN ANTI-TUMOR RESEARCH OF RECOMBINANT PHAGE VACCINE EXPRESSED XENOGENIC EGFR

ER-α36: a Novel Biomarker and Potential Therapeutic Target in Breast Cancer.

Estrogen-independent Effects of ER-α36 in ER-negative Breast Cancer

Inhibition of Tumor Growth by Recombinant Adenovirus Containing Human Lactoferrin Through Inducing Tumor Cell Apoptosis in Mice Bearing Emt6 Breast Cancer

ERα36 is an Effective Target of Epigallocatechin-3-gallate in Hepatocellular Carcinoma.

Immunotherapy of EGFR-positive Tumor Based on Recombinant EGFR Phage Vaccine

The function of silence ER-α36 gene and its impact on MDA-MB-231 cells of estrogen receptor-negative breast cancer

Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by prostate-specific membrane antigen (PSMA) enhancer/promoter.

Experimental Study of Breast Cancer Treatment with Recombinant EGFR Antisense Adenovirus

Cloning and expression of a novel target fusion protein and its application in anti-tumor therapy

A Targeted Immunotherapy Approach for HER2/neu Transformed Tumors by Coupling an Engineered Effector Domain with Interferon-Γ

Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor.

The Construction of Anti-EGFR Single Chain Variable Fragment Fused with Gelonin Toxin Prokaryotic Expressing Plasmid and the Study of Its Anti-tumor Effects

A novel conditionally replicating "armed" adenovirus selectively targeting gastrointestinal tumors with aberrant wnt signaling

Construction of Recombinant Adenovirus Expressing the Small Interfering RNA of Vascular Endothelial Growth Factor-C

The Study of Adenovirus Mediated Biospecific Antibody Fusion Protein Targeting to EGFR and HER2

Impact of ER520, a Candidate of Selective Estrogen Receptor Modulators, on in Vitro Cell Growth, Migration, Invasion, Angiogenesis and in Vivo Tumor Xenograft of Human Breast Cancer Cells

Expression of xenogentic epidermal growth factor receptor ectodomain and its antitumor effect]